[Levonorgestrel-releasing intrauterine system and combined oral contraceptives as conservative treatments for recurrent ovarian endometriosis: a comparative clinical study].
Xiao-wen Xu,
Xiaowen Xu,
Le-dan Wang,
Xueqiong Zhu,
Xue-qiong Zhu,
Linzhi Yan,
Lin-zhi Yan,
Yutao Guan,
Yu-tao Guan,
Shi-chai Zhu,
Yue Hu
article
OA: closed
CC0
⤵ 6 in-corpus citations
⚙
AI-generated summary
by claude@2026-06, 2026-06-08
ⓘ
This study found that both LNG-IUS and COC treatments reduced endometriotic cysts and pain, but LNG-IUS demonstrated greater cyst size reduction and fewer systemic side effects compared to COC.
Abstract
OBJECTIVE: To evaluate and compare the efficiency and safety of levonorgestrel-releasing intrauterine system (LNG-IUS) and combined oral contraceptives (COC) in the treatment of recurrent ovarian endometriosis after conservative surgery or conservative surgery plus medical therapy. METHODS: A total of 48 patients with recurrent ovarian endometriosis underwent randomization. The regimens of LNG-IUS (n = 24) and COC (n = 24) were offered. The volume of ovarian endometriotic cysts was recorded before treatment and at 6, 12, 18 and 24 months. The volume of ovarian endometriotic cysts, pain score of visual analogue scale (VAS), menstrual pattern, body weight, serum CA125 and serum lipids were compared to the pretreatment level within each treatment group, as well as between two treatment groups during the same period. RESULTS: (1) At 18 months after LNG-IUS, the cysts in 2 subjects entirely disappeared. At 24 months, 18 patients had a disappearance of cysts. The overall size reduction was statistically significant (9.2 ± 3.0) vs (0.9 ± 1.5) cm(3) (P < 0.01). In the COC group, 12 subjects had a complete resolution of cysts at 24 months. The overall size reduction was statistically significant (9.4 ± 2.2) vs (2.9 ± 3.1) cm(3) (P < 0.01). At 18 & 24 months, the cyst size reduction was significantly larger in the LNG-INS group than the COC group (2.4 ± 1.5) vs (4.7 ± 2.6) cm(3) (P < 0.01) and (0.9 ± 1.5) vs (2.9 ± 3.1) cm(3) (P < 0.05); (2) There was a significant improvement of dysmenorrhea, chronic pelvic pain and dyspareunia at 6- & 12-month follow-up in both groups; (3) serum CA125 decreased at 6 & 12 months in both groups with statistical significance. It decreased more sharply in the LNG-IUS group and remained at low levels beyond 12 months; (4) within 6 months of LNS-IUS, irregular bleeding and spotting were the major side effects. Beyond that period the symptoms were significantly relieved. Weight gain and dyslipidemia were the major side effects of COC. CONCLUSION: For patients with recurrent ovarian endometriosis after conservative surgery or conservative surgery plus medical therapy, LNG-IUS and COC may be used to control and reduce endometriotic cysts, relieve pain and reduce the level of CA125. LNG-IUS has the advantages of a greater convenience and minor systemic side effects.
My notes (saved in your browser only)
Outcome instruments
VAS-pain
Condition tags
endometriosischronic_pelvic_paindysmenorrheadyspareunia
MeSH descriptors
Contraceptives, Oral, Combined
Endometriosis
Levonorgestrel
Ovarian Cysts
Adult
Combined Modality Therapy
Contraceptives, Oral, Combined
Endometriosis
Endometriosis
Female
Humans
Levonorgestrel
Levonorgestrel
Ovarian Cysts
Ovarian Cysts
Recurrence
Treatment Outcome
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and
that cite this one (upper rings, green). Dot size scales with the
paper's in-corpus citation count — bigger dot = more influential
within the endo/adeno field. Click a dot to open that paper.
[ expand to 2 hops ]
— adds papers reached through this work's immediate
citers/citees. Heavier; up to 60 extra dots.
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:16:42.478857+00:00
License: CC0
· commercial use OK